tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Stephen Brozak, 244 are a BUY (71.35%), 44 are a SELL (12.87%), 54 are a HOLD (15.79%).
Analyst Stephen Brozak, currently employed at WBB, carries an average stock price target met ratio of 52% that have a potential upside of 16.01% achieved within 80 days.
Stephen Brozak’s has documented 33 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CFRX, ContraFect Corp at 08-Jun-2022.
Analyst best performing recommendations are on PRTK (PARATEK PHARMACEUTICALS).
The best stock recommendation documented was for PRTK (PARATEK PHARMACEUTICALS) at 4/23/2021. The price target of $10 was fulfilled within 46 days with a profit of $2.22 (28.53%) receiving and performance score of 6.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
2 years 8 months 17 days ago
(05-Apr-2022)
0/2 (0%)
$330.4 (106.72%)
Buy
3 years 21 days ago
(01-Dec-2021)
0/1 (0%)
$642 (161.31%)
Buy
$880
$879.49 (172449.02%)
$880
3 years 3 months 8 days ago
(14-Sep-2021)
0/2 (0%)
$578.6 (230.24%)
$480
$471.5 (5547.06%)
$640
4 years 1 months 10 days ago
(12-Nov-2020)
0/3 (0%)
$167.6 (53.65%)
Buy
$17
5 years 5 months 10 days ago
(12-Jul-2019)
0/1 (0%)
$8 (88.89%)
What Year was the first public recommendation made by Stephen Brozak?
